Co-Diagnostics, Inc.(CODX) fills in demand for existing test kits
Co-Diagnostics, Inc. currently trades at $9.10 and has seen losses of -23% in the past month. Co-Diagnostics, Inc. has seen an increase in revenue in the past four quarters. In recent news, the global shortage of COVID-19 testing kits is hitting the United States and other nations hard, but a recent FDA policy change means that Co-Diagnostics (CODX) can help meet this unprecedented demand by aggressively distributing its COVID-19 test without prior FDA clearance. This makes Co-Diagnostics, Inc. a great buy because the company plans to rapidly begin fulfilling orders from a multitude of U.S. customers, including thousands of additional laboratories that can now run the company’s test as a clinical diagnostic. Co-Diagnostics, Inc.’s dividends sit at 0% and has a market cap of $227.46 million. In the past 5 years, the stock has risen 59%, making the company something add to your portfolio. Overall, Co-Diagnostics, Inc. is a stock you want to keep an eye out for. Yesterday the stock closed at $8.96 leaving investors up 16% in the past 24 hours. Co-Diagnostics, Inc.’s high 1-year forecast is 20 with a low of 5.